https://naveris.com/press-release/new-saliva-test-detects-head-and-neck-cancer/2023-10-30T18:25:40+00:00https://naveris.com/press-release/naveris-congratulates-scientific-advisors-bhisham-chera-and-gaorav-gupta-on-presentation-of-clinical-data-at-the-2018-astro-annual-meeting-2/2024-12-28T05:27:25+00:00https://naveris.com/press-release/naveris-inc-raises-19-million-in-financing-to-advance-and-commercialize-blood-tests-for-early-detection-of-hpv-and-other-viral-related-cancers-i/2025-02-04T16:57:28+00:00https://naveris.com/press-release/blood-test-accurately-identifies-hpv-related-head-and-neck-cancer-recurrence-prospective-clinical-study-published-in-journal-of-clinical-oncology/2024-12-27T08:05:29+00:00https://naveris.com/press-release/naveris-head-and-neck-cancer-recurrence-detection-study-selected-for-presentation-at-astro-2022-plenary-session-2/2024-12-28T05:28:04+00:00https://naveris.com/press-release/naveris-announces-abstract-accepted-for-presentation-at-the-2022-american-society-for-clinical-oncology-asco-annual-meeting/2024-12-27T08:08:13+00:00https://naveris.com/press-release/naveris-inc-raises-51-million-to-advance-commercialization-of-navdx/2024-12-28T05:33:55+00:00https://naveris.com/press-release/naveris-collaborators-present-award-winning-abstract-at-astro-2022-on-potential-of-navdx-to-inform-treatment-strategies-in-hpv-driven-cancers/2024-12-28T05:12:13+00:00https://naveris.com/press-release/mayo-clinic-collaborates-with-naveris-to-advance-precision-medicine-in-hpv-driven-head-and-neck-cancer-with-navdx-in-dart-2-0-clinical-trial/2024-12-27T08:07:23+00:00https://naveris.com/press-release/naveris-announces-new-data-featuring-navdx-in-oral-highlight-and-poster-presentations-at-upcoming-astro-and-aao-hnsf-2023-meetings/2024-12-28T04:57:15+00:00https://naveris.com/press-release/naveris-announces-two-peer-review-publications-validating-navdx-performance-in-daily-clinical-practice/2024-12-28T05:02:01+00:00https://naveris.com/press-release/naveris-receives-medicare-coverage-for-navdx-test/2025-02-04T16:39:31+00:00https://naveris.com/press-release/naveris-announces-commercial-payor-coverage-for-navdx-test-from-highmark-inc/2025-05-10T11:17:36+00:00https://naveris.com/press-release/naveris-announces-new-data-at-astro-multidisciplinary-head-and-neck-cancers-symposium-2024/2025-02-04T16:35:31+00:00https://naveris.com/press-release/naveris-unveils-navigate-hpv-a-groundbreaking-registry-to-advance-hpv-driven-cancer-diagnosis-and-treatment/2025-02-04T16:41:47+00:00https://naveris.com/press-release/naveris-announces-new-data-at-eurogin-international-multidisciplinary-hpv-congress-2024/2025-02-04T16:36:15+00:00https://naveris.com/press-release/naveris-awarded-adlt-status-by-cms-for-the-navdx-test/2025-02-04T16:37:03+00:00https://naveris.com/press-release/naveris-announces-launch-of-phase-ii-clinical-study-in-mrd-head-and-neck-cancer/2025-02-04T16:34:36+00:00https://naveris.com/press-release/naveris-to-present-new-data-highlighting-clinical-utility-of-the-navdx-test-at-the-2024-asco-annual-meeting/2025-06-16T10:08:52+00:00https://naveris.com/press-release/new-multicenter-study-highlights-use-of-the-navdx-test-in-resolving-clinically-indeterminate-findings/2025-02-04T16:41:58+00:00https://naveris.com/press-release/naveris-presents-new-data/2025-02-04T16:49:32+00:00https://naveris.com/press-release/naveris-to-showcase-advances/2025-02-04T16:40:58+00:00https://naveris.com/press-release/naveris-announces-expanded/2025-02-04T16:33:37+00:00https://naveris.com/press-release/naveris-announces-expansion-of-the-navdx-test-in-anal-cancer-molecular-residual-disease-surveillance/2025-02-04T12:55:28+00:00https://naveris.com/press-release/naveris-announces-medicare-coverage-of-the-navdx-test-in-anal-cancer-molecular-residual-disease-surveillance/2025-11-18T03:52:15+00:00https://naveris.com/press-release/naveris-to-highlight-new-publications-at-the-44th-annual-j-p-morgan-healthcare-conference/2026-01-09T17:29:33+00:00